Zoetis Inc. (NYSE:ZTS) Stock Holdings Increased by Czech National Bank

Czech National Bank lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 6.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 92,291 shares of the company’s stock after purchasing an additional 5,339 shares during the quarter. Czech National Bank’s holdings in Zoetis were worth $18,032,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Webster Bank N. A. increased its stake in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the period. Quarry LP grew its holdings in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the period. Neo Ivy Capital Management purchased a new position in Zoetis in the 4th quarter worth about $40,000. LRI Investments LLC purchased a new stake in shares of Zoetis in the 1st quarter valued at approximately $43,000. Finally, Hazlett Burt & Watson Inc. lifted its holdings in shares of Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after purchasing an additional 102 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 0.5 %

Shares of Zoetis stock traded down $0.96 during trading on Friday, hitting $190.03. 1,421,979 shares of the stock traded hands, compared to its average volume of 2,576,563. The stock has a market cap of $86.09 billion, a P/E ratio of 36.61, a PEG ratio of 2.95 and a beta of 0.89. The company has a fifty day moving average price of $187.30 and a two-hundred day moving average price of $175.45. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.41 earnings per share. Equities research analysts predict that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.